A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

NCT06328673 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: DM919
DRUG: Pembrolizumab

Sponsor

D2M Biotherapeutics Inc.